News | Molecular Imaging | July 17, 2015

New Study Backs Molecular Breast Imaging for Diagnosis of Invasive Lobular Carcinoma

Researchers in Oregon report 88.9 percent sensitivity with Dilon Molecular Imaging System

Dilon, molecular breast imaging, MBI/BSGI, ILC, invasive lobular carcinoma

July 17, 2015 - Molecular breast imaging (MBI/BSGI) has been proven to be a highly sensitive imaging technique for the diagnosis of invasive lobular carcinoma (ILC), a position supported by a recent publication in the Journal of the American Medical Association Surgery. Physicians at the Legacy Cancer Institute in Portland, Oregon, reported a sensitivity of 88.9 percent for MBI/BSGI in diagnosing ILC, a difficult-to-diagnose breast cancer.

This study was a retrospective review of a prospectively maintained imaging registry at the institution in the course of six years. The analysis was conducted with almost 700 patients who underwent the BSGI procedure, which to date makes it the largest pool of data on molecular imaging of ILCs. The results show that BSGI has a slightly higher sensitivity for the detection of ILCs than for the detection of invasive ductal carcinomas (IDCs), while the specificities for both diseases are comparable. BSGI was also reported to detect additional cancers in patients with ILC. BSGI was found to have advantages over magnetic resonance imaging (MRI), as it is easier to interpret, better tolerated by patients and much less costly. The group of physicians concluded that BSGI has high sensitivity and specificity and is an excellent adjunctive imaging tool for patients with newly diagnosed ILCs.

The MBI for the study was conducted using a Dilon molecular imaging system, a high-resolution, small field-of-view gamma camera, optimized to perform MBI. With MBI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as "hot spots" on the MBI image.

For more information: www.dilon.com

Related Content

Doctor-Patient Discussions Neglect Potential Harms of Lung Cancer Screening
News | Lung Cancer | August 15, 2018
August 15, 2018 — Although national guidelines advise doctors to discuss the benefits and harms of...
Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Konica Minolta Hosting Lunch and Learn at 23rd Annual Mammography Meeting in Santa Fe
News | Breast Imaging | July 31, 2018
Konica Minolta Healthcare Americas Inc. will sponsor a lunch and learn featuring its Exa Mammo platform during the 23rd...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal. The FDA granted approval of the Sentimag System to Endomagnetics Inc.

The  Endomagnetics' Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal.

Technology | Women's Health | July 24, 2018
July 24, 2018 — The U.S.
Overlay Init